2011-10-14T13:03:09-05:00 2010-11-30 Deloitte Tax LLP 200 Renaissance Center STE 3900 Detroit MI 48243 990 2009-12-01 522000823 VAN ANDEL RESEARCH INSTITUTE VANA 6162345000 333 BOSTWICK Avenue NE GRAND RAPIDS MI 49503 Timothy Myers 6162345368 2011-10-14 1 3133963000 2009 2016-03-07 17:11:31Z TIMOTHY J MYERS 333 BOSTWICK Avenue NE GRAND RAPIDS MI 49503 79263260 0 X WWW.VAI.ORG X 1996 MI Medical Research Organization 6 3 248 0 839181 181235 43991473 69868505 1854145 1332729 626862 -272304 4460793 5766282 50933273 76695212 221029 0 18873211 22508665 0 407930 30800458 69776826 49673669 92506520 1259604 -15811308 250543499 253776425 287653664 312690617 -37110165 -58914192 Medical Research Organization 0 0 2105245 The laboratory of structural sciences is focused on studying the structures and functions of protein/ligand complexes that play key roles in major hormone signaling pathways. See schedule O for further information about this program. 1394369 The laboratory of Molecular Oncology has focused on understanding the numerous and diverse roles that MET plays in malignant progression and metastasis. Schedule O provides further information regarding this program's accomplishment. 929297 The laboratory of cancer and developmental cell biology is focused on understanding anthrax lethal factor, as well as working with the Canine Hereditary Cancer Consortium to study cancer within canines to discover the genomic causes of disease in both canines and people. Schedule O provides further information regarding this program's accomplishments. 68273236 68273236 72702147 1 1 0 1 0 0 1 0 0 1 0 1 0 0 1 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 1 108 0 248 1 1 1 0 0 0 0 0 0 0 0 6 3 0 1 1 0 0 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MI X TIMOTHY J MYERS 6162345368 333 BOSTWICK Avenue NE GRAND RAPIDS MI 495032518 DAVID VAN ANDEL 40.00 X X 414308 0 39326 GEORGE VANDE WOUDE 40.00 X X 320002 0 41487 Dr James Fahner 1.00 X 15000 0 0 Dr FRITZ ROTTMAN PHD 1.00 X 11000 4000 0 DR JEFFREY TRENT 40.00 X X 0 87170 1463 JOSE CARDENAS 1.00 X 0 0 0 R JACK FRICK 40.00 X 269728 0 49762 STEVE HEACOCK 40.00 X 314433 0 49362 Joseph Gavan 40.00 X 187611 0 32112 TIMOTHY MYERS 40.00 X 137189 0 18371 LINDA ZARZECKI 40.00 X 143913 0 18841 JEFFREY BATTERSHALL 1.00 X 0 0 0 KATHleen VOGELSANG 40.00 X 251394 0 20221 Ted Heilman 40.00 X 211555 0 19424 Dr H Eric Xu 40.00 X 199344 0 22373 Dr James Resau 40.00 X 181995 0 22258 JOHN BENDER 40.00 X 0 0 0 BRYON CAMPBELL 40.00 X 179709 0 21433 2837181 91170 356433 30 0 1 0 HUNT - OWEN AMES & KIMBALL (See Schedule 6720 SCOTTSDALE DR STE 300 SCOTTSDALE AZ 85253 CONSTRUCTION SERVICES 32089485 Bank of AmericaMerrill Lynch 100 N Tryon St Charlotte NC 28263 Credit Enhancement Fees 1135277 rafael vinoly pc 50 van dam street new york NY 10013 architecture/ design 683534 translational genomics institute 445 n fifth st suite 600 phoenix AZ 85004 contract labor 560936 warner norcross & judd 111 lyon st 900 old kent grand rapids MI 495032487 legal/ consulting 500800 24 63319977 5652752 895776 69868505 Research billed rev 541700 1332729 504558 828171 1332729 202696 202696 24016 24016 319808 319808 2019921 15165 1053328 5655 966593 9510 976103 965093 11010 1010049 1509065 -499016 -499016 -499016 Rel. Party Admin Suppo 561000 3858580 3858580 Gain on Joint Ventures 523000 827697 827697 Reimbursed Expenses 900099 154548 154548 -370454 -432354 61900 4470371 76695212 5224558 839181 762968 221029 221029 3622793 1329366 2293427 14603433 8675344 5673361 254728 1093027 670914 407337 14776 2049319 1258578 762372 28369 1140093 700361 423774 15958 1050515 66018 984497 150165 150165 112499 112499 2207131 1372375 834756 619288 59022 560266 147402 76802 70600 408781 155053 253728 2521237 2044462 476775 756248 594240 162008 127649 92028 35621 13165289 10509819 2655470 8753752 7318541 1435211 400688 188774 211914 TGEN CONTRIBUTION PAYAB 29228120 29228120 Lab Supplies & Services 3117006 3101120 15886 EQUIPMENT & SOFTWARE 1703707 997274 706433 TGEN INTEGRATION 1245773 1245773 MSU DISCOUNT ON PAYABLE 1000746 1000746 3060830 1796388 1170343 94099 92506520 72702147 19396443 407930 14724976 6671503 1392801 2623400 2589305 1236706 1492741 2351000 842304 823236 264311645 44532823 201916499 219778822 16821154 1887951 97917 97917 10665802 18305890 250543499 253776425 25230783 25465798 977793 1453448 220000000 220000000 385000 41060088 65771371 287653664 312690617 X -37614343 -39862048 503178 -19053644 1000 1500 -37110165 -58914192 250543499 253776425 X 0 1 1 X 1 1 X SPECTRUM HEALTH GRAND RAPIDS MI RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 1 0 0 0 0 1 84375 0 1 28124 112499 0 Part II-B, Line 1i: Explanation of Other Lobbying Activities: John Van Fossen / Clark Hill: State of Michigan: MET WITH MICHIGAN ECONOMIC DEVELOPMENT CORPORATION, OFFICE OF GOVERNOR GRANHOLM, OFFICE OF LT. GOVERNOR JOHN CHERRY, MICHIGAN STATE SENATE and HOUSE OF REPRESENTATIVEs, AND ATTORNEY GENERAL OF MICHIGAN - LIFE SCIENCE PROGRAMS AND FUNDING; MICHIGAN DEPARTMENT OF COMMUNITY HEALTH RESEARCH AND HEALTH CARE SUPPORT PROGRAMS FEDERAL GOVERNMENT: FUNDING FOR NCI/ NIH; AND STEM EDUCATION PROGRAMS 435037 X 0 1 1 218579630 20716931 197862699 38634573 23793217 14841356 7097442 22675 7074767 219778822 BOND ISSUANCE COSTS NET OF ACCUMULATED AMORTIZATION 1615890 Pledged Securities 16690000 18305890 ACCRUED POSTRETIREMENT BENEFIT OBLIGATION 1065477 Unrealized Loss on Bond Swap 36022174 MSU Med School - Contribution Payable 9364776 Capital Lease 90824 TGEN - CONTRIBUTION PAYABLE 19228120 65771371 76695212 92506520 -15811308 227235 -6219955 -5992720 -21804028 73039851 227235 227235 72812616 3882596 3882596 76695212 94843878 6219955 6219955 88623923 3882596 3882596 92506519 Part III, Line 4: The glass Chihuly sculpture is a unique, one-of-a-kind Chandelier reminiscent of the DNA double helix. The Chandelier, which is placed in the reception area, provides motivation and inspiration as Scientists are driven to understand the genetic basis of diseases in their pursuit of cures and other therapies. Part V, Line 4: Description of Intended Use of Endowment Funds: TO SUPPORT THE CORE RESEARCH OF VARI BY SUPPLYING A STEADY SOURCE OF INCOME FOR ITS OPERATING BUDGETS. PART VI, LINE 1B: THE INCREASE IN BUILDING BOOK VALUE REFLECTS THE 240,000 SQUARE FOOT PHASE II EXPANSION. THE PHASE II EXPANSION OF VARI NEARLY TRIPLED LABORATORY SPACE AND ALLOWS FOR CURRENT AND FUTURE GROWTH OF PROGRAMS AND EXPANDED RESEARCH SUCH AS NEURODEGENERATIVE DISEASES THROUGH THE JAY VAN ANDEL PARKINSONS RESEARCH LAB. Part X: In June 2006, FASB issued ASC 740, Income Taxes (formerly FASB Interpretation (FIN) No. 48, Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109). ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting for interim periods, disclosure, and transition. ASC 740 is effective for fiscal years beginning after December 15, 2008. This standard was adopted for fiscal year ended November 30, 2010 and had no material impact on the consolidated financial statements. Part XI, Line 8 and Part XIII Line 2d: NET LOSS RELATED TO THE INTEREST RATE SWAP. Part XII and XIII, Line 4b: Expense reimbursements Part V - All endowment funds are held at the Van Andel Institute (a related organization). East Asia & the Pacific 0 0 program services Research COllaboration - Legal Fees. 37768 0 0 37768 1 Friends of Crescent Park 333 Bostwick Avenue NE Grand Rapids MI 49503 264562012 501(c)3 205579 Support Crescent Park Renovation 1 0 graduate student stipends for van andel graduate school and michigan state university students 9 171062 FOREIGN NATIONAL STUDENT STIPENDS 16 67424 Procedure for Monitoring Grants in the U.S.: Part I, Line 2: Schedule I, Part I, Line 2: VARI donated land improvements to the Friends of Crescent Park (FOCP), a 501(c)(3) organization dedicated to preserving, improving, expanding, and promoting Crescent Park, a city of Grand Rapids public park adjacent to VARI's facility. The board of trustees approved this donation via its annual budget approval process. Other Information: Part IV: SCHEDULE I, PART I, LINE 2: FUNDS PROVIDED TO THE RESEARCH STUDENTS ARE CONTINUALLY MONITORED WHICH ENSURES THAT ALL FUNDS ARE MISSION-DRIVEN. STIPENDS ARE PROVIDED DIRECTLY TO THE STUDENTS FOR LIVING ASSISTANCE. THESE EXPENDITURES ARE MADE AT THE DISCRETION OF THE BOARD OF TRUSTEES. X X X 0 1 X X X X X 1 1 0 0 0 0 0 0 0 DAVID VAN ANDEL 301378 0 92252 0 20678 0 38886 0 440 0 453634 0 0 0 GEORGE VANDE WOUDE 301030 0 0 0 18972 0 40250 0 1237 0 361489 0 0 0 R JACK FRICK 215921 0 52517 0 1290 0 40650 0 9112 0 319490 0 0 0 STEVE HEACOCK 239709 0 57534 0 17190 0 40250 0 9112 0 363795 0 0 0 Joseph Gavan 151611 0 35700 0 300 0 23000 0 9112 0 219723 0 0 0 TIMOTHY MYERS 126473 0 10468 0 248 0 9259 0 9112 0 155560 0 0 0 LINDA ZARZECKI 132576 0 10740 0 597 0 9729 0 9112 0 162754 0 0 0 KATHleen VOGELSANG 158545 0 92399 0 450 0 11550 0 8671 0 271615 0 0 0 Ted Heilman 142383 0 68744 0 428 0 10312 0 9112 0 230979 0 0 0 Dr H Eric Xu 184051 0 14843 0 450 0 13262 0 9111 0 221717 0 0 0 Dr James Resau 179837 0 178 0 1980 0 13147 0 9111 0 204253 0 0 0 BRYON CAMPBELL 165103 0 13916 0 690 0 13262 0 9111 0 202082 0 0 0 Part I, Line 1a VARI allows for first-class or charter travel to officers and Trustees. Fitness center membership dues were paid by VARI for Steve Heacock totaling $500. There is not a policy for Housing allowance or residence for personal use. This is offered only on rare occasions and for special circumstances. Human Resources manages this on a case by case basis. Part I, Line 1b A written policy is in place for first class/ charter travel and Health/ Social club dues/ fees. Supplemental Information Part III PART I, LINE 4A: SEVERANCE PAID TO STEVE HEACOCK TOTALED $448,871 IN FISCAL YEAR 2010, $0 CALENDAR YEAR 2009 PART I, LINE 4B: STEVE HEACOCK $5,077 FISCAL YEAR 2010,$16,500 CALENDAR YEAR 2009 GEORGE VANDE WOUDE $16,500 FISCAL YEAR 2010 AND CALENDAR YEAR 2009 Supplemental Information Part III PART II: DR. JEFFREY TRENT WAS EMPLOYED BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED PARTY, DURING CALENDAR YEAR 2009. TGEN BECAME A RELATED PARTY TO VARI AS OF DECEMBER 1, 2009. ONE MONTH OF COMPENSATION IS THEREFORE REPORTED ON VARI'S FORM 990 PART VII AND SCHEDULE J PART II. Michigan Strategic Fund Limited Obligation Revenue 521417332 594698EG3 2008-04-10 220000000 BUILD, EQUIP & FURNISH PHASE II RESEARCH FACILITY, & REFUND $50M PRIOR LTD 0 0 223159144 141613 3159144 1794232 112039949 2009 1 0 1 1 0 1 1 1 1 0.00000 0.00440 0.00440 1 1 1 0 0 0 0 DR JEFFREY TRENT Officer 1235000 House Purchase 0 Form 990, Part VI, Section A, line 3 Jerry Callahan, an Independent Contractor, serves as the Vice President of Business Development and Technology Transfer. Form 990, Part VI, Section A, line 4 FORM 990, PART VI, SECTION A, LINE 4: THE VAN ANDEL RESEARCH INSTITUTE (VARI) AMENDED THEIR TRUST AGREEMENT TO GIVE AUTHORITY TO THE VAN ANDEL INSTITUTE BOARD OF DIRECTORS TO APPOINT AND REMOVE THE TRUSTEES OF VARI. Form 990, Part VI, Section A, line 7a THE TRUSTEES OF VAN ANDEL INSTITUTE HAVE THE AUTHORITY TO ELECT ONE OR MORE MEMBERS OF THE GOVERNING BODY. Form 990, Part VI, Section B, line 11 Following completion of the financial audit, the Form 990 is prepared and reviewed by management. It is then circulated to the full Board for review and final approval prior to filing with the IRS. Form 990, Part VI, Section B, line 12c VARI has a written conflict of interest policy for which the organization enforced a process to identify, evaluate, and correct or remove potential conflicts of interest. The Van Andel Institute administers the conflict of interest (COI) policy through two committees: the Individual COI committee and the Institutional COI committee. The COI policy serves as guide for all staff members of the organization. The policy is intended to 1) provide staff with a useful resource when developing activities with outside industry and 2) provide assurance to staff that there is a committee to review and resolve potential conflicts of interest if / when they arise. The Individual COI committee, chaired by the Director of Compliance, generates an annual disclosure questionnaire distributed to all staff to enforce the policy. The conflicts committee is responsible for making recommendations to the Director. Resolutions are implemented with approval of the committee and in discussion with the VAI Chairman. The COI policy also serves as a guide for all members of the Board of Trustees and senior executives. The Institutional COI committee requires Trustees to complete an annual disclosure statement. This statement affirms their understanding of the policy, requires their acknowledgement of the organization's nonprofit status, and requests disclosure if / when potential conflicts arise. In the event a potential conflict arises at the Board or senior officer level, the Office of the General Counsel reviews and meets with the Board of Trustees to resolve potential conflicts. Form 990, Part VI, Section B, line 15 Compensation for the CEO, Executive Management Officials, Executive Director, officers, and key employees is reviewed and approved annually by the independent compensation committee. The compensation committee is under the Van Andel Institute board of trustees, although all employees are employed by either Van Andel Research Institute or Van Andel Education Institute. Records and documentation, including comparability data, are kept and support decisions made on behalf of these arrangements and are contemporaneously documented. Form 990, Part VI, Section C, line 19 These documents are available to the public upon request. Form 990, Part III, Lines 4a-4c VARI's three largest program services by expenses Line 4a - Program service activity #1 The laboratory of Structural Sciences is focused on studying the structures and functions of protein/ ligand complexes that play key roles in major hormone signaling pathways. The laboratory also works on exploring the structural information to develop therapeutic agents for treating human disease, including cancer and diabetes. Lab studies use multidisciplinary approaches, including molecular and cellular biology, biochemistry, animal physiology, and x-ray crystallography. Research in this group currently focuses on three areas: nuclear hormone receptors, the met tyrosine kinase receptor, and G protein-coupled receptors. These proteins, beyond their fundamental roles in biology, are important drug targets. In addition, this lab has extended their research to plant hormone abscisic acid (ABA) receptors. Recently they determined the structure of GR bound to deacylcortivazol (DAC), which binds to GR with 200-fold more potency than cortisol, the physiological glucocorticoid. The GR DAC structure reveals that the GR ligand binding pocket can be expanded dramatically, to twice its normal size. This new pocket provides a tremendous opportunity for drug design and screening. Using a computational screen, the lab identified several nonsteroidal ligands that like dissociated glucocorticoids in our cell-based assay. The lab is now running animal studies to confirm the physiological activities of these novel nonsteroidal ligands, which could lead to new methods of treating inflammation and autoimmune diseases. The lab has determined crystal structures of the ligand binding domain of the PTH and CRF receptors, and we are developing hormone analogs for treating osteoporosis, depression, and diabetes. Line 4b - Program service activity #2 Since discovering MET in 1984, and its ligand hepatocyte growth factor (HGF) in 1991, the laboratory of Molecular Oncology has focused on understanding the numerous and diverse roles that MET and HGF/SF plays in malignant progression and metastasis. Met is a transmembrane protein found in many different types of human cells. Increased expression of this protein has been found in most human solid tumors. The lab staff has developed antibodies against the Met protein that allow them to determine the location of cells that produce Met, and radiolabeled antibodies allow the imaging of tumors within living tissue. These antibodies have been shown to be valuable reagents for detecting cells that express Met. Studies are underway to determine for a variety of cancers the percentage that express the Met protein and to determine the feasibility of using Met expression or anti-Met antibodies as detection and prognostic tools for physicians. Recent lab achievements include the finding that MET may be an important target for an aggressive form of breast cancer, the development of important animal models for evaluating the efficacy of anti-HGF and/or anti-MET therapeutics, and the development of animal models for investigating the factors that modulate glioblastoma growth and evaluating therapeutic agents. Animal models are uniquely suited for evaluating new therapeutics, both alone and in combination with other therapeutics. Line 4c - Program service activity #3 The Laboratory of Cancer and Developmental Cell Biology is collaborating with various other physicians to try to exploit the properties of anthrax lethal factor and develop a new way to fight cancers such as melanoma, as well as to provide insight into the regulation of growth and vascularization of soft-tissue cancers called sarcomas. Recently the lab received funding to investigate the genetic causes of cancer including sarcomas in dogs. This lab has also been highly involved in rallying an unprecedented national alliance of veterinarians, basic scientists, and clinicians to form the Canine Hereditary Cancer Consortium (CHCC). The CHCC will integrate genomic studies of dogs with phenotypic and pharmacologic tests to predict therapies for human disease. This strategy leverages the low genetic diversity of pure bred dogs coupled with their predisposition for particular cancers to identify the underlying genetic lesions and biochemical pathways that contribute to these diseases, and then translate these discoveries to humans. Over the course of the last year, members of the CHCC have begun to define the fundamental goals that would characterize its growth with respect to cancer discovery in the coming decade. In the next two years the lab will focus our efforts on unraveling the genetic causes of several cancers, including but not limited to: hemangiosarcoma, osteosarcoma, melanoma, malignant histiocytic sarcoma, and lymphoma. The goals are ambitious but this is a one-time opportunity to make an incredible difference in the diagnosis and treatment of cancer in not only humans but also dogs. Line 4d - All other program service activities The Van Andel Research Institute (VARI) is dedicated to improving human health by determining the molecular basis of disease, utilizing genetics, bio-chemistry, structural and molecular biology, and chemistry. VARI's current focus is on building programs in basic sciences related to improving our understanding of cancer, including research programs in functional genomics, as well as, initial research efforts in neurological disorders, Parkinson's disease, and other devastating diseases. VARI has also made a long-term commitment to the development of programs that facilitate the translations of discoveries into therapeutic strategies for improving human health. VARI has over 30 program service accomplishments because of its varied reearch endeavors. In 2010, VARI researchers identified many disease related findings including potential ways to diagnose and treat several types of cancer. Researchers found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against a form of kidney cancer. They also found a protein that may serve as a useful biomarker to predict patients' response to sunitinib treatment. The study of salivary gland cancer led to the discovery that the approved drug rapamycin may have great potential in the treatment of this cancer. A new method was developed to better study the cells that line and protect the prostate in relation to the development of cancer. Using this model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments. In collaboration with researchers at other organizations, a biomarker that could help in the treatment of patients with an aggressive type of lung cancer was discovered. Researchers identified an enzyme that could help diagnose and treat a form of liver cancer. A method was developed to predict whether pancreatic cysts are benign or are precursors to invasive cancer. Pancreatic cancer is often diagnosed in advanced stages beyond standard treatment options; detecting the cancer early could save many lives. Researchers also found that the protein PEBP1 could be a diagnositic marker for pancreatic cancer. PART IV, LINE 32 VARI NET ASSETS SHOULD BE CONSIDERED ON A CONSOLIDATED BASIS WITH VAN ANDEL INSTITUTE (VAI), VAN ANDEL EDUCATION INSTITUTE, AND THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, RELATED PARTIES. ON A CONSOLIDATED BASIS, NET ASSETS ARE $925,926,000 PER AUDITED FINANCIAL STATEMENTS. THE NEGATIVE NET ASSETS AT VARI ARE DUE TO VAI FUNDING EXPENSES ON A CASH BASIS. THEREFORE, ACCRUALS CAUSE NET ASSETS TO BE NEGATIVE. Form 990, Part VII, Section B Compensation for Hunt - Owen Ames & Kimball excludes estimated materials and includes estimated labor on Hunt managed sub-contractors. form 990, part VII, Section A Dr. Jeffrey Trent is not an independent voting member of the board for fiscal year ending November 30, 2010, because he was paid compensation. His compensation through VARI began in January 2010, and therefore, is not included in part VII, section A, column D. Compensation from the Translational Genomics Research Institute (TGEN), a related party beginning December 1, 2009, is included for the period December 1, 2009 through December 31, 2009. During this time period, Dr. Trent spent the majority of his time (51%) on VARI matters with the reminder of such time (approximately 49%) devoted to TGEN matters. form 990, part VII, Section B JEFFREY BATTERSHALL IS LISTED AS SECRETARY ON PAGE 7. HE IS CONTRACTED THROUGH THE LAW FIRM WARNER, NORCROSS, & JUDD. ALL PAYMENTS FOR HIS SERVICES ARE PAID DIRECTLY TO WARNER, NORCROSS, & JUDD. FORM 990, PART IX, COLUMN D FUNDRAISING EXPENSES AT VARI WERE INCURRED TO SUPPORT THE MISSION OF THE RESEARCH INSTITUTE THROUGH GRANT SOLICITATION AND EXTRAMURAL PROPOSAL PREPARATION. FORM 990, PART XI, LINE 2C THE PROCESS FOR SELECTING THE AUDITOR FOR VAN ANDEL RESEARCH INSTITUTE'S FINANCIAL STATEMENTS DID NOT CHANGE DURING 2010. form 990, Schedule R, Part II VARI became the sole member of the Translational Genomics Research Institute (TGen), an Arizona nonprofit, as of December 1, 2009. TGen has been recognized by the IRS as a tax-exempt corporation under section 501(c)(3) of the Code. THE primary mission of TGEN is to make and translate genomic discoveries into advances in human health. TGen has the following wholly owned entities that were created to support TGen through various functions: The Translational Genomics Research Institute Foundation (Foundation), TGen Accelerator Management, LLC, The Center for Translational Drug Development (TD2), and International Biosciences Commercialization Consortium, LLC (IBCC). VAI INNOVATIONS LLC 333 Bostwick Avenue NE GRAND RAPIDS MI 49503 522000823 Licensing Intellectual Property of VARI MI -762427 10974 N/A VARI International 333 Bostwick Avenue NE GRAND RAPIDS MI 49503 262615936 Biomedical research MI -47441 1268631 N/A XB TRANSMED SOLUTIONS LLC 333 Bostwick Avenue NE GRAND RAPIDS MI 49503 203947727 TRANSLATIONAL MEDICAL SOFTWARE AND SERVICES MI 181241 N/A BOSTWICK EVENT MANAGEMENT 333 Bostwick Avenue NE GRAND RAPIDS MI 49503 522000823 EVENT MANAGEMENT MI -43636 N/A paradise valley property llc 333 Bostwick Avenue NE grAND RAPIDS MI 49503 522000823 property transactions MI 0 0 N/A Van Andel Institute 333 BOstwick Avenue NE Grand Rapids MI 495032518 522000820 Supporting organization for VARI and VAEI MI 501(c)(3) 11c N/A Van Andel Education Institute 333 BOstwick Avenue NE Grand Rapids MI 495032518 522000824 Operating a School MI 501(c)(3) 2 N/A Van andel Institute Graduate School 333 BOstwick Avenue NE Grand Rapids ME 495032518 203340886 Operating a School MI 501(c)(3) 2 Van Andel Education Institute THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 MEDICAL RESEARCH AZ 501(c)(3) 7 VAN ANDEL RESEARCH INSTITUTE TGEN RESEARCH INSTITUTE FOUNDATION 400 E VAN BUREN SUITE 850 PHOENIX AZ 85004 331092191 FUNDRAISING AZ 501(c)(3) 7 N/A TRANSMED SYSTEMS INC 21170 CANYON OAK WAY CUPERTINO CA 95014 272358859 TRANSLATIONAL MEDICAL SOFTWARE AND SERVICES CA VAN ANDEL RESEARCH INSTITUTE C -410129 178450 0.55900 1 1 1 0 1 0 0 0 0 0 0 0 1 1 1 1 1 0 Van Andel Institute C 63319977 Van Andel Institute E 236690000 Van Andel Institute O 201052 Van Andel Education Institute P 1278596 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE Q 10000000 THE TRANSLATIONAL GENOMIC RESSEARCH INSTITUTE Q 1078497 THE TRANSLATIONAL GENOMIC RESEARCH INSTITUTE N 340951 THE TRANSLATIONAL GENOMIC RESEARCH INSTITUTE C 1234367 THE TRANSLATIONAL GENOMIC RESEARCH INSTITUTE K 42680 van andel institute graduate school B 8022 TRANSMED SYSTEMS INC A 100000 TRANSMED SYSTEMS INC B 500000